Immix Biopharma raises ~$93.7M net via 19.1M share and warrant offering at $5.10

Immix Biopharma, Inc.

19,117,646 shares at $5.10/share and 490,196 pre-funded warrants at $5.09/warrant in underwritten offering.
Net proceeds expected ~$93.7M after underwriting discounts and estimated expenses.
Underwriting agreement with Morgan Stanley & Co. LLC as representative of underwriters.
Offering expected to close December 9, 2025, subject to customary closing conditions.
Pre-funded warrants exercisable immediately at $0.01/share, with 4.99% beneficial ownership limitation.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Immix Biopharma, Inc. entered into Underwriting Agreement with Morgan Stanley & Co. LLC valued at 19,117,646 shares at $5.10 per share and pre-funded warrants to purchase 490,196 shares at $5.09 per (effective 2025-12-07).

Action: entry
Agreement: underwriting
Counterparty: Morgan Stanley & Co. LLC
Value: 19,117,646 shares at $5.10 per share and pre-funded warrants to purchase 490,196 shares at $5.09 per
Effective: 2025-12-07

Exact text from the filing

On December 7, 2025, Immix Biopharma, Inc., a Delaware corporation (the “ Company ”), entered into an underwriting agreement (the “ Underwriting Agreement ”) with Morgan Stanley & Co. LLC, as representative of the several underwriters named in Schedule 1 thereto (the “ Underwriters ”), relating to the issuance and sale (the “ Offering ”) of 19,117,646 shares of its common stock, par value $0.0001 per share (the “ Shares ”), and pre-funded warrants to purchase 490,196 shares of its common stock (the “ Pre-Funded Warrants ”).

View on SEC.gov

Browse all material agreements →

Immix Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-026697

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.